Cargando…

Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-κB signaling pathway

Lung cancer is the leading cause of cancer-associated mortality worldwide. Cisplatin (DDP) is a first-line chemotherapeutic drug for the treatment of lung cancer; however, the majority of patients develop resistance to DDP. P-glycoprotein (P-gp), also referred to as multidrug resistance (MDR) protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Wencui, Ling, Xiaoming, Chen, Ying, Wu, Xiaoli, Zhao, Zhongquan, Wang, Wenwu, Wang, Shuiliang, Lai, Guoxiang, Yu, Zongyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053858/
https://www.ncbi.nlm.nih.gov/pubmed/32124932
http://dx.doi.org/10.3892/ijmm.2020.4485
_version_ 1783503117774487552
author Kong, Wencui
Ling, Xiaoming
Chen, Ying
Wu, Xiaoli
Zhao, Zhongquan
Wang, Wenwu
Wang, Shuiliang
Lai, Guoxiang
Yu, Zongyang
author_facet Kong, Wencui
Ling, Xiaoming
Chen, Ying
Wu, Xiaoli
Zhao, Zhongquan
Wang, Wenwu
Wang, Shuiliang
Lai, Guoxiang
Yu, Zongyang
author_sort Kong, Wencui
collection PubMed
description Lung cancer is the leading cause of cancer-associated mortality worldwide. Cisplatin (DDP) is a first-line chemotherapeutic drug for the treatment of lung cancer; however, the majority of patients develop resistance to DDP. P-glycoprotein (P-gp), also referred to as multidrug resistance (MDR) protein 1, is associated with an MDR phenotype, which results in failure of cancer chemotherapy; thus, identifying effective MDR pump inhibitors may improve the outcomes of patients who develop resistance to treatment. Hesperetin is a derivative of hesperidin, which is extracted from tangerine peel and exhibits multiple antitumor properties. In the present study, human lung adenocarcinoma A549 and A549/DDP cells were treated with different concentrations of hesperetin and DDP, respectively. Furthermore, rhodamine 123 efflux assays, Cell Counting Kit-8 assays, immunofluorescence, reverse transcription-quantitative PCR and western blot analysis were used to elucidate the mechanisms underlying the effects of hesperetin On A549/DDP cells. Additionally, a xenograft model of lung cancer in nude mice was established to explore the effects of hesperetin on A549/DDP cell growth in vivo. The results demonstrated that hesperetin sensitized A549/DDP cells to DDP. In vivo, hesperetin pretreatment significantly inhibited tumor growth. Mechanistically, hesperetin markedly decreased the expression of P-gp and increased the intracellular accumulation of the P-gp substrate, rhodamine 123, in A549/DDP cells. In addition, pretreatment of A549/DDP cells with hesperetin significantly inhibited nuclear factor (NF)-κB (p65) activity and its nuclear translocation. Taken together, the results of the present study suggest that hesperetin reversed P-gp-mediated MDR by decreasing P-gp expression in A549/DDP cells, which was associated with inhibition of the NF-κB signaling pathway. These findings may provide the basis for the use of hesperetin clinically to reverse MDR.
format Online
Article
Text
id pubmed-7053858
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-70538582020-03-18 Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-κB signaling pathway Kong, Wencui Ling, Xiaoming Chen, Ying Wu, Xiaoli Zhao, Zhongquan Wang, Wenwu Wang, Shuiliang Lai, Guoxiang Yu, Zongyang Int J Mol Med Articles Lung cancer is the leading cause of cancer-associated mortality worldwide. Cisplatin (DDP) is a first-line chemotherapeutic drug for the treatment of lung cancer; however, the majority of patients develop resistance to DDP. P-glycoprotein (P-gp), also referred to as multidrug resistance (MDR) protein 1, is associated with an MDR phenotype, which results in failure of cancer chemotherapy; thus, identifying effective MDR pump inhibitors may improve the outcomes of patients who develop resistance to treatment. Hesperetin is a derivative of hesperidin, which is extracted from tangerine peel and exhibits multiple antitumor properties. In the present study, human lung adenocarcinoma A549 and A549/DDP cells were treated with different concentrations of hesperetin and DDP, respectively. Furthermore, rhodamine 123 efflux assays, Cell Counting Kit-8 assays, immunofluorescence, reverse transcription-quantitative PCR and western blot analysis were used to elucidate the mechanisms underlying the effects of hesperetin On A549/DDP cells. Additionally, a xenograft model of lung cancer in nude mice was established to explore the effects of hesperetin on A549/DDP cell growth in vivo. The results demonstrated that hesperetin sensitized A549/DDP cells to DDP. In vivo, hesperetin pretreatment significantly inhibited tumor growth. Mechanistically, hesperetin markedly decreased the expression of P-gp and increased the intracellular accumulation of the P-gp substrate, rhodamine 123, in A549/DDP cells. In addition, pretreatment of A549/DDP cells with hesperetin significantly inhibited nuclear factor (NF)-κB (p65) activity and its nuclear translocation. Taken together, the results of the present study suggest that hesperetin reversed P-gp-mediated MDR by decreasing P-gp expression in A549/DDP cells, which was associated with inhibition of the NF-κB signaling pathway. These findings may provide the basis for the use of hesperetin clinically to reverse MDR. D.A. Spandidos 2020-04 2020-02-05 /pmc/articles/PMC7053858/ /pubmed/32124932 http://dx.doi.org/10.3892/ijmm.2020.4485 Text en Copyright: © Kong et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Kong, Wencui
Ling, Xiaoming
Chen, Ying
Wu, Xiaoli
Zhao, Zhongquan
Wang, Wenwu
Wang, Shuiliang
Lai, Guoxiang
Yu, Zongyang
Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-κB signaling pathway
title Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-κB signaling pathway
title_full Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-κB signaling pathway
title_fullStr Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-κB signaling pathway
title_full_unstemmed Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-κB signaling pathway
title_short Hesperetin reverses P-glycoprotein-mediated cisplatin resistance in DDP-resistant human lung cancer cells via modulation of the nuclear factor-κB signaling pathway
title_sort hesperetin reverses p-glycoprotein-mediated cisplatin resistance in ddp-resistant human lung cancer cells via modulation of the nuclear factor-κb signaling pathway
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053858/
https://www.ncbi.nlm.nih.gov/pubmed/32124932
http://dx.doi.org/10.3892/ijmm.2020.4485
work_keys_str_mv AT kongwencui hesperetinreversespglycoproteinmediatedcisplatinresistanceinddpresistanthumanlungcancercellsviamodulationofthenuclearfactorkbsignalingpathway
AT lingxiaoming hesperetinreversespglycoproteinmediatedcisplatinresistanceinddpresistanthumanlungcancercellsviamodulationofthenuclearfactorkbsignalingpathway
AT chenying hesperetinreversespglycoproteinmediatedcisplatinresistanceinddpresistanthumanlungcancercellsviamodulationofthenuclearfactorkbsignalingpathway
AT wuxiaoli hesperetinreversespglycoproteinmediatedcisplatinresistanceinddpresistanthumanlungcancercellsviamodulationofthenuclearfactorkbsignalingpathway
AT zhaozhongquan hesperetinreversespglycoproteinmediatedcisplatinresistanceinddpresistanthumanlungcancercellsviamodulationofthenuclearfactorkbsignalingpathway
AT wangwenwu hesperetinreversespglycoproteinmediatedcisplatinresistanceinddpresistanthumanlungcancercellsviamodulationofthenuclearfactorkbsignalingpathway
AT wangshuiliang hesperetinreversespglycoproteinmediatedcisplatinresistanceinddpresistanthumanlungcancercellsviamodulationofthenuclearfactorkbsignalingpathway
AT laiguoxiang hesperetinreversespglycoproteinmediatedcisplatinresistanceinddpresistanthumanlungcancercellsviamodulationofthenuclearfactorkbsignalingpathway
AT yuzongyang hesperetinreversespglycoproteinmediatedcisplatinresistanceinddpresistanthumanlungcancercellsviamodulationofthenuclearfactorkbsignalingpathway